The Company is a Korea-based company principally engaged in the research and development of bio therapeutic drugs. The products mainly consist of ulcerative colitis medicine BBT-401, autoxin inhibitor BBT-877, non-small cell lung cancer medicine BBT-176, and others. The Company is also involved in the manufacture of basic pharmaceuticals and biologicals. The Company was established on September 17, 2015. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on December 20, 2019.
Headquarters
303, 58, Pangyo-Ro 258Beon-Gil, Bundang-Gu, Seongnam-Si, Gyeonggi-Do
Seongnam; Gyeonggi;
Contact Details: Purchase the Bridge Biotherapeutics, Inc. report to view the information.
Website: http://www.bridgebiorx.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service